144eP Real-world use of carboplatin in ER/PR-negative, HER2-positive early breast cancer

The role of carboplatin in ER/PR-negative, HER2-positive breast cancer remains variable in routine clinical practice, particularly in the neoadjuvant setting. Evidence from real-world cohorts describing treatment selection and associated outcomes in this molecular subtype is limited.